Review

TECHNOLOGY-BASED EVALUATION IN PARKINSONISM

Volume: 46 Number: 3 September 30, 2024
EN TR

TECHNOLOGY-BASED EVALUATION IN PARKINSONISM

Abstract

Parkinson's disease is a neurodegenerative disorder characterized by motor and non-motor symptoms that worsen over time. Today, traditional clinical assessment methods are used to monitor disease progression and evaluate treatment responses. However, these methods are subjective and may fail to measure specific conditions. In recent years, thanks to advances in wearable technologies, smart sensors, and data analysis, technology-based approaches to the assessment of patients with Parkinson's disease have gained more attention. With these technologies, objective data can be obtained by monitoring patients' daily activities, motor functions, and symptoms. Motor symptoms such as tremor severity, rigidity, bradykinesia, postural instabilities, freezing phenomenon, and motor parameters of speech impairment can be objectively measured through these technologies. Furthermore, the ability to remotely transmit these data allows patients to be assessed in their own homes and provides continuous feedback to healthcare professionals. This review highlights the importance and potential of technology-based assessment methods in Parkinson's patients and aims to guide future research.

Keywords

References

  1. 1. Fahn S. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease. 1987:153-63.
  2. 2. Balestrino R, Schapira A. Parkinson disease. European journal of neurology. 2020;27(1):27-42. doi: 10.1111/ene.14108.
  3. 3. Güler, S., Caylan, A., Turan, F. N., & Dağdeviren, N. (2022). Prevalence and Clinical Features of Idiopathic Parkinson’s Disease in Western Turkey. Archives of Neuropsychiatry, 59(2), 98. doi: 10.29399/npa.27486.
  4. 4. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta‐analysis. Movement disorders. 2014;29(13):1583-90. doi: 10.1002/ mds.25945.
  5. 5. Dorsey ER, Bloem BR. The Parkinson pandemic—a call to action. JAMA neurology. 2018;75(1):9-10. doi: 10.1001/ jamaneurol.2017.3299.
  6. 6. Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):939-53. doi: 10.1016/S1474-4422(18)30295-3.
  7. 7. Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry. 2020;91(8):795-808. doi: 10.1136/jnnp-2019-322338.
  8. 8. Wolters EC. Variability in the clinical expression of Parkinson's disease. Journal of the neurological sciences. 2008;266(1-2):197-203. doi: 10.1016/j.jns.2007.08.016.

Details

Primary Language

English

Subjects

Primary Health Care , Health and Community Services

Journal Section

Review

Publication Date

September 30, 2024

Submission Date

July 8, 2024

Acceptance Date

August 10, 2024

Published in Issue

Year 2024 Volume: 46 Number: 3

AMA
1.Balki S, Nacar E, Özkan RS, Karakurt M. TECHNOLOGY-BASED EVALUATION IN PARKINSONISM. CMJ. 2024;46(3):156-163. doi:10.7197/cmj.1512299